NBC Los Angeles11h
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
WFIU12h
Midwest state attorneys general call for the FDA to clamp down on counterfeit obesity drugs
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the U.S. Food and Drug Administration to take action against “bad actors” selling counterfeit weight loss drugs.
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
Campaign US1d
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...
WFYI1d
Indiana joins states calling for the FDA to clamp down on counterfeit weight loss drugs
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...
STAT1d
Pharmalittle: We’re reading about HHS reducing public comment, a Lilly obesity drug ad, and more
HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...
BioSpace1d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...